Anti‐angiogenic therapy using vascular endothelial growth factor (VEGF)‐neutralization antibodies and tyrosine kinase inhibitors have been reported to improve clinical outcome in several types of cancers, such as colon cancers.2 Here, VEGFA is linked to malignant colon neoplasm.